News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
139,833 Results
Type
Article (4728)
Company Profile (90)
Press Release (135015)
Multimedia
Podcasts (3)
Webinars (6)
Section
Business (44670)
Career Advice (209)
Deals (6823)
Drug Delivery (13)
Drug Development (18402)
Employer Resources (19)
FDA (1709)
Job Trends (2892)
News (70780)
Policy (4081)
Tag
2024 BioCapital Digital (2)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (3)
2024 Biotech Bay Standard (5)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (6)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (4)
2025 Lone Star Bio Digital (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Genetown Standard (1)
2026 Pharm Country Standard (1)
Academia (306)
Adcomms (1)
Allergies (16)
Alliances (12679)
ALS (29)
Alzheimer's disease (333)
Antibody-drug conjugate (ADC) (27)
Approvals (1720)
Artificial intelligence (50)
Autoimmune disease (11)
Automation (3)
Bankruptcy (38)
Best Places to Work (2336)
BIOSECURE Act (13)
Biosimilars (10)
Biotechnology (85)
Bladder cancer (20)
Brain cancer (6)
Breast cancer (73)
Cancer (557)
Cardiovascular disease (16)
Career advice (197)
Career pathing (4)
CAR-T (56)
Cell therapy (169)
Cervical cancer (6)
Clinical research (14941)
Collaboration (267)
Compensation (117)
Complete response letters (2)
COVID-19 (457)
CRISPR (9)
C-suite (103)
Cystic fibrosis (28)
Data (581)
Depression (7)
Diabetes (50)
Diagnostics (798)
Digital health (1)
Diversity, equity & inclusion (8)
Drug discovery (43)
Drug pricing (5)
Drug shortages (2)
Duchenne muscular dystrophy (20)
Earnings (13218)
Editorial (4)
Employer resources (19)
Events (25566)
Executive appointments (265)
FDA (1951)
Featured Employer (13)
Frontotemporal dementia (5)
Funding (221)
Gene editing (23)
Generative AI (4)
Gene therapy (84)
GLP-1 (116)
Government (366)
Guidances (9)
Healthcare (1790)
Huntington's disease (6)
IgA nephropathy (7)
Immunology and inflammation (25)
Indications (9)
Infectious disease (485)
Inflammatory bowel disease (51)
Inflation Reduction Act (1)
Influenza (16)
Intellectual property (36)
Interviews (18)
IPO (3111)
IRA (4)
Job creations (695)
Job search strategy (185)
Kidney cancer (1)
Labor market (7)
Layoffs (37)
Legal (764)
Liver cancer (13)
Lung cancer (42)
Lymphoma (51)
Management (5)
Manufacturing (86)
MASH (10)
Medical device (569)
Medtech (569)
Mergers & acquisitions (3913)
Metabolic disorders (117)
Multiple sclerosis (23)
NASH (1)
Neurodegenerative disease (16)
Neuropsychiatric disorders (3)
Neuroscience (456)
NextGen: Class of 2025 (891)
Non-profit (274)
Northern California (811)
Now hiring (5)
Obesity (60)
Opinion (37)
Ovarian cancer (29)
Pain (21)
Pancreatic cancer (22)
Parkinson's disease (39)
Partnered (4)
Patents (56)
Patient recruitment (27)
Peanut (12)
People (16964)
Pharmaceutical (10)
Phase I (5843)
Phase II (7097)
Phase III (3758)
Pipeline (318)
Policy (25)
Postmarket research (249)
Preclinical (2484)
Press Release (51)
Prostate cancer (18)
Psychedelics (2)
Radiopharmaceuticals (50)
Rare diseases (72)
Real estate (1542)
Recruiting (10)
Regulatory (3265)
Reports (13)
Research institute (316)
Resumes & cover letters (20)
RSV (4)
Schizophrenia (12)
Series A (41)
Series B (28)
Service/supplier (3)
Sickle cell disease (11)
Southern California (738)
Special edition (1)
Spinal muscular atrophy (36)
Sponsored (4)
Startups (1045)
State (1)
Stomach cancer (2)
Supply chain (18)
Tariffs (3)
The Weekly (3)
United States (6213)
Vaccines (77)
Venture capitalists (7)
Weight loss (21)
Women's health (4)
Worklife (2)
Date
Today (6)
Last 7 days (139)
Last 30 days (680)
Last 365 days (9074)
2025 (2559)
2024 (9486)
2023 (10278)
2022 (13453)
2021 (13957)
2020 (10817)
2019 (7295)
2018 (5660)
2017 (6599)
2016 (6019)
2015 (7050)
2014 (5393)
2013 (4438)
2012 (4849)
2011 (5270)
2010 (4845)
Location
Africa (139)
Alabama (30)
Alaska (1)
Arizona (26)
Arkansas (2)
Asia (8926)
Australia (2117)
California (1863)
Canada (548)
China (108)
Colorado (29)
Connecticut (65)
Delaware (25)
Europe (22478)
Florida (175)
Georgia (27)
Idaho (11)
Illinois (129)
India (4)
Indiana (93)
Iowa (1)
Japan (41)
Kansas (11)
Kentucky (2)
Louisiana (1)
Maine (2)
Maryland (215)
Massachusetts (1372)
Michigan (72)
Minnesota (95)
Missouri (8)
Montana (8)
Nebraska (2)
Nevada (4)
New Hampshire (5)
New Jersey (420)
New Mexico (6)
New York (443)
North Carolina (271)
North Dakota (3)
Northern California (811)
Ohio (38)
Oklahoma (5)
Oregon (4)
Pennsylvania (411)
Puerto Rico (3)
Rhode Island (5)
South America (214)
South Carolina (1)
Southern California (738)
Tennessee (15)
Texas (227)
Utah (22)
Virginia (10)
Washington D.C. (7)
Washington State (316)
Wisconsin (7)
139,833 Results for "immatics biotechnologies gmbh".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Immatics Announces Full Year 2024 Financial Results and Business Update
March 28, 2025
·
24 min read
Press Releases
Zymo Research Responds to Recent Court Ruling in Litigation with QIAGEN GmbH
March 19, 2025
·
1 min read
Press Releases
T-CURX GmbH Enters into Technology Access Agreement with Kytopen
February 14, 2025
·
5 min read
Collaboration
BMS’ Cost-Cutting Campaign Claims Collabs With Immatics, Century
Bristol Myers Squibb aims to generate around $1.5 billion in savings through 2025—a goal that it hopes to reach by lowering third-party expenditures, focusing only on key growth brands and cutting some 2,200 jobs by year-end.
December 16, 2024
·
2 min read
·
Tristan Manalac
Business
Immatics Announces First Quarter 2024 Financial Results and Business Update
Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, provided a business update and reported financial results for the quarter ended March 31, 2024.
May 14, 2024
·
20 min read
Press Releases
Immatics Announces Pricing of $150 Million Public Offering
October 11, 2024
·
3 min read
Press Releases
Immatics Announces Proposed $150 Million Public Offering
October 10, 2024
·
3 min read
Press Releases
Gift of Life Biologics and Cellex Cell Professionals GmbH Celebrate Successful Partnership to Deliver High-Quality Starting Materials for Final Drug Product Manufacturing in Cell and Gene Therapy
April 8, 2025
·
4 min read
Business
Immatics Announces Full Year 2023 Financial Results and Corporate Update
Immatics N.V. provided a business update and reported financial results for the quarter and full year ended December 31, 2023.
March 21, 2024
·
19 min read
Press Releases
Swarm Oncology Ltd. and Cellex Cell Professionals GmbH Announce Strategic Partnership to Advance Swarm’s Innovative T Cell Therapies for Solid Cancers
February 25, 2025
·
3 min read
1 of 13,984
Next
